AF 18FU 1625

DOCKET NO. 217408US0CONT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Chika NAKANISHI et al

SERIAL NO:

10/022,874

FILED:

December 20, 2001

FOR:

DIHYDROPYRIDINE DERIVATIVES

GROUP ART UNIT: 1625

MM 2 1, 2005 EXAMINER: MORRIS, P. L.

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The Applicants wish to make of record the references listed on the attached Form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACT

Please charge any additional fees not payment is enclosed herewith, or credit any overpayment is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Stephen G. Baxter

Registration No. 32,884

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Form PTO 1449		U.S. DEPARTMENT	OF COMMERCE	ATTY DOCKET NO.		SERIAL NO.			
Modified) PATENT AND TRADEMARK OFFICE		217408US0CONT	10/022,874						
		/0	IPE	APPLICANT	· ·				
LIST OF	REFE	RENCES CITED BY AP	PLICANT 7	Chika NAKANISHI et al					
MAY 2 4 2005				FILING DATE	GROUP				
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\				December 20, 2001	1625				
		ENT.	PRADEMARY	U.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS IF		FILING DATE APPROPRIATE	
	AA	4,616,002	10/07/86	Bruno KAMBER et al					
	AB	5,767,131	06/16/98	Charles GLUCHOWSKI et al				<u> </u>	
	AC			·					
	· AD								
	AE		·						
	AF								
	AG							***	
	AH								
	Al			·					
	AJ								
	AK								
	AL								
	AM								
	AN								
			FO	REIGN PATENT DOCUMENTS					
		DOCUMENT	T 5	COLINTRY		TRANSLATION			
		NUMBER	DATE	COUNTRY		YES	S	. NO	
	AO	WO 99/43658	09/02/99	WIPO					
	AP	0 520 200	12/30/92	EPO					
	AQ	08-041052	02/13/96	JAPAN (w/attached English abstract)				XXX	
	AR	0 622 364	11/02/94	EPO					
	AS	WO 94/22829	10/13/94	WIPO					
	AT	62-175462	08/01/87	JAPAN	_			XXX	
	AU								
	AV								
		OTHER RE	FERENCES (Including Author, Title, Date, Pertine	nt Pages, e	tc.)			
	AW	Brian COX et al, Exp. (Opin. Ther. Pa	tents, "N-type calcium channel blockers	in pain and	stroke", 1	998, 8(10), pp. 1237-	
	AX	Peter R. DODD et al, Neurochem. Int., "Excitotoxic Mechanisms in The Pathogenesis of Dementia", 1994, Vol. 25, No. 3, pp. 203-219.							
	AY	Klaus W. LANGE et al, Neuroscience and Biobehavioral Reviews, "Dopamine/Glutamate Interactions in Parkinson's Disease", 1997, Vol. 21, No. 4, pp. 393-400.							
	AZ	Karl D. KIEBURTZ et a Dysfunction in the Acq	Addi	Additional References sheet(s) attached					
	L	Complex", December	pp. 1201-1204.	Date Considered					
Examiner									

		ATTY DOCKET NO.	SERIAL NO.				
Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	217408US0CONT	10/022,874				
	SIPE	APPLICANT					
LIST OF REFE	RENCES CITED BY APPLICANTS	Chika NAKANISHI et al					
	MAY 2 1 2005 2	FILING DATE	GROUP				
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	December 20, 2001	1625				
	CA. LARY	(Including Author, Title, Date, Pertinent I	Pages, etc.)				
AAA	Toshio IMAIZUMI et al, Brain Resea matter", 1999, Vol. 817, pp. 84-92.	rch, "The role of voltage-gated Ca ^{z+} channe	els in anoxic injury of spinal cord white				
AAB	Ken P. MADDEN et al, Brain Research, "Treatment with conotoxin, an 'N-type' calcium channel blocker, in neuronal hypoxic-ischemic injury", Vol. 537, 1990, pp. 256-262.						
AAC	D. M. WHITE et al, Brain Research, "Effect of subcutaneous administration of calcium channel blockers on nerve injury-induced hyperalgesia", 1998, Vol. 801, pp. 50-58.						
AAD	Laura BASILICO et al, European Journal of Pharmacology, "Influence of ω -conotoxin on morphine analgesia and withdrawal syndrome in rates", 1992, Vol. 218, pp. 75-81.						
AAE	R. C. PIERCE et al, The Journal of Pharmacology Experimental Therapeutics, "Calcium-Mediated Second Messengers Modulate the Expression of Behavioral Sensitization to Cocaine", 1998, Vol. 286, No. 3, pp. 1171-1176.						
AAF	Kazuyuki MURASE et al, Brain Research, "Serotonin suppresses <i>N</i> -methyl-D-aspartate responses in acutely isolated spinal dorsal horn neurons of the rat", Vol. 525, 1990, pp. 84-91.						
AAG	Dhanapalan NAGARATHNAM et al, J. Med. Chem., "Design and Synthesis of Novel a_{1a} Adrenoceptor-Selective Dihydropyridine Antagonists for the Treatment of Benign Prostatic Hyperplasia", Vol., 41, 1998, pp. 5320-5333.						
ААН	Wai C. WONG et al, J. Med. Chem., "Identification of a Dihydropyridine as a Potent α _{1a} Adrenoceptor Selective Antagonist That Inhibits Phenylephrine-Induced Contraction of the Human Prostate", Vol. 41, 1998, pp. 2643-2650.						
AAI	J. B. SAINANI et al, Indian Journal of Chemistry, "Formation of 1,4,5,6,7,8-hexahydro-pyrido[4,3-b]pyridine by Hantzsch synthesis", Vol. 34B, January 1995, pp. 17-20.						
AAJ							
AAK							
AAL							
ААМ							
AAN							
AAO							
AAP							
AAQ							
Examiner			Date Considered				
*Examiner: Initial if a conformance and no	reference is considered, whether or no ot considered. Include copy of this form	ot citation is in conformance with MPEP 609 in with next communication to applicant.); Draw line through citation if not in				